ViroPharma Incorporated Provides Update From Ongoing Phase 2 Studies...

ViroPharma is currently conducting two Phase 2 dose ranging studies of oral maribavir at one of three doses in transplant recipients.

http://www.biospace.com/news_story.aspx?StoryID=301356&full=1